Grant: CIHR Fellowship
University of Toronto
$135,000.00
Generating insulin-producing cells from adult pancreatic stem cells in order to provide a beta-cell source for transplantation in diabetes treatment.
FY 2008-09
Summary
Type1 diabetes (T1D) is a disease characterized by high blood glucose due to lack of insulin production after destruction of pancreatic beta-cells followed by vascular complications that can devastate the patients' lives. Islet transplantation has been reported to be successful in therapy of T1D, however a shortage in donor organ/tissue is a huge limitation for this treatment strategy. The ability of stem cells to expand, differentiate into specialized cells and potentially reconstruct tissues provides promising tools for treatment of diseases caused by tissue damage such as T1D.
Embryonic stem cell (ESC) research has attracted a lot of attention and is a very powerful implement in regenerative medicine, however the dangers of strong proliferative/tumorogenic and unpredictive differentiating capabilities of ESCs make adult tissue stem cells/progenitors a more reliable and attractive tool. Isolation of adult pancreatic stem cells that can differentiate into insulin producing cells is an important achievement that can provide a great source for islet transplantation therapies.
We have isolated adult mouse and human pancreatic stem cells and shown that they give rise to insulin producing cells ex vivo. The characteristics of these cells are not fully understood. This project is focused on characterizing the pancreatic stem cells and enhancing their ability to generate insulin producing pancreatic β-cells. We also want to transplant these β-cells into animal models of diabetes to test their ability in normalizing the high blood sugar. Successful achievements will grant a great source and potent means for regenerative treatment of T1D in humans.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
174351
Name
Razavi Rozita
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Generating insulin-producing cells from adult pancreatic stem cells in order to provide a beta-cell source for transplantation in diabetes treatment.
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Development; Diabetes; Pancreas; Regenerative; Stem Cell
Abstract
Type1 diabetes (T1D) is a disease characterized by high blood glucose due to lack of insulin production after destruction of pancreatic beta-cells followed by vascular complications that can devastate the patients' lives. Islet transplantation has been reported to be successful in therapy of T1D, however a shortage in donor organ/tissue is a huge limitation for this treatment strategy. The ability of stem cells to expand, differentiate into specialized cells and potentially reconstruct tissues provides promising tools for treatment of diseases caused by tissue damage such as T1D.
Embryonic stem cell (ESC) research has attracted a lot of attention and is a very powerful implement in regenerative medicine, however the dangers of strong proliferative/tumorogenic and unpredictive differentiating capabilities of ESCs make adult tissue stem cells/progenitors a more reliable and attractive tool. Isolation of adult pancreatic stem cells that can differentiate into insulin producing cells is an important achievement that can provide a great source for islet transplantation therapies.
We have isolated adult mouse and human pancreatic stem cells and shown that they give rise to insulin producing cells ex vivo. The characteristics of these cells are not fully understood. This project is focused on characterizing the pancreatic stem cells and enhancing their ability to generate insulin producing pancreatic β-cells. We also want to transplant these β-cells into animal models of diabetes to test their ability in normalizing the high blood sugar. Successful achievements will grant a great source and potent means for regenerative treatment of T1D in humans.
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Razavi, Rozita
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~